rolongation has been observed with use of efavirenz. Dolasetron has been associated with a dose-dependant prolongation in the QT, PR, and QRS intervals on an electrocardiogram. In addition, efavirenz may induce the CYP3A4 metabolism of dolasetron; potentially reducing the efficacy of dolasetron by decreasing its systemic exposure.
Efavirenz; Emtricitabine; Tenofovir: Although data are limited, coadministration of efavirenz and dolasetron may increase the risk for QT prolongation and torsade de pointes (TdP). QT prolongation has been observed with use of efavirenz. Dolasetron has been associated with a dose-dependant prolongation in the QT, PR, and QRS intervals on an electrocardiogram. In addition, efavirenz may induce the CYP3A4 metabolism of dolasetron; potentially reducing the efficacy of dolasetron by decreasing its systemic exposure.
Elbasvir; Grazoprevir: Administering dolasetron with grazoprevir may result in elevated dolasetron plasma concentrations. Dolasetron is a substrate of CYP3A; grazoprevir is a weak CYP3A inhibitor. If these drugs are used together, closely monitor for signs of adverse events.
Eliglustat: Coadministration of dolasetron and eliglustat may result in increased plasma concentrations of dolasetron and an increased risk of QT prolongation. If coadministration is necessary, use great caution and monitor closely. Dolasetron is a CYP2D6 substrate associated with dose-dependent PR, QRS, and/or QT prolongation. Eliglustat is a CYP2D6 inhibitor that is predicted to cause PR, QRS, and/or QT prolongation at significantly elevated plasma concentrations. Coadministration of these agents may have additive effects on the QT interval.
Emtricitabine; Rilpivirine; Tenofovir alafenamide: Due to a possible risk for QT prolongation and torsade de pointes (TdP), dolasetron and rilpivirine should be used together cautiously. Dolasetron has been associated with a dose-dependant prolongation in the QT, PR, and QRS intervals on an electrocardiogram. Use of dolasetron injection for the prevention of chemotherapy-induced nausea and vomiting is contraindicated because the risk of QT prolongation is higher with the doses required for this indication; when the injection is used at lower doses (i.e., those approved for post-operative nausea and vomiting) or when the oral formulation is used, the risk of QT prolongation is lower and caution is advised. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation; caution is advised when administering rilpivirine with other drugs that may prolong the QT or PR interval.
Emtricitabine; Rilpivirine; Tenofovir disoproxil fumarate: Due to a possible risk for QT prolongation and torsade de pointes (TdP), dolasetron and rilpivirine should be used together cautiously. Dolasetron has been associated with a dose-dependant prolongation in the QT, PR, and QRS intervals on an electrocardiogram. Use of dolasetron injection for the prevention of chemotherapy-induced nausea and vomiting is contraindicated because the risk of QT prolongation is higher with the doses required for this indication; when the injection is used at lower doses (i.e., those approved for post-operative nausea and vomiting) or when the oral formulation is used, the risk of QT prolongation is lower and caution is advised. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation; caution is advised when administering rilpivirine with other drugs that may prolong the QT or PR in |
